Associated Papers
Detection rates of multigene panel and exome testing in patients with previous negative BRCA1/2 results.
Wasson JL et al.
Familial Cancer, 2025
T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
Wagner MW et al.
Ajnr. American Journal of Neuroradiology, 2023
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
α-Fetoprotein-Producing Hepatoid Gastric Adenocarcinoma With Osteoclast-Like Giant Cells and Neuroendocrine Differentiation: A Case Study With Molecular Profiling.
Wincewicz A et al.
International Journal of Surgical Pathology, 2015
Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
Sewell A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Janku F et al.
Cell Reports, 2014
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P et al.
Molecular Cancer Therapeutics, 2013
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F et al.
Cancer Research, 2013
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
Zhang H et al.
Breast Cancer Research and Treatment, 2008
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Saal LH et al.
Cancer Research, 2005